BDB 201
Alternative Names: BDB-201Latest Information Update: 21 Apr 2021
Price :
$50 *
At a glance
- Originator Seven and Eight Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma; Solid tumours
Most Recent Events
- 01 Apr 2021 Phase-III clinical trials in Malignant melanoma in USA (unspecified route), before April 2021 (Seven and Eight Biopharmaceuticals pipeline, April 2021)
- 01 Apr 2021 Phase-III clinical trials in Solid tumours in USA (unspecified route), before April 2021 (Seven and Eight Biopharmaceuticals pipeline, April 2021)